// March 01, 2024
Innovating for Individual Care: The Impact of USP on Personalized Medicine
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
This year has seen a flurry of activity by the U.S.
USP’s Naiffer Romero has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life S
This summer, a wave of regulatory activity on nitrosamines has taken place, with agencies fro